Fig 1: Detection of IL-28B (IFNL3) and IL-28 receptor alpha (IL-28RA) in kidney tissue of lupus patients with nephritis. IFNL3 detected on parietal cells (red arrow), podocytes (yellow arrows), and tubular cells (blue arrows) of kidney from lupus patient with minimal change disease (a) and lupus patient with class IV proliferative nephritis (b). IL-28RA expressed in parietal cells (red arrow), podocytes (yellow arrows), and tubular cells (blue arrows) of kidney from patient with minimal change disease (c) and lupus patient with class IV proliferative nephritis (d)
Fig 2: Association of serum IFNL3 levels with SLEDAI and complement depression. a IFNL3 levels significantly (unpaired t test t = 5.974, P < 0.0001) increased in high SLEDAI SLE patients (SLEDAI > 4, N = 19; IFNL3 concentration 9.190 ± 1.351 pg/ml) compared to low SLEDAI SLE patients (SLEDAI = 4, N = 51; IFNL3 concentration 3.413 ± 0.3171 pg/ml). b IFNL3 levels also significantly (unpaired t test t = 3.362, P = 0.0013) higher in SLE patients (N = 14) with complement C3 plus C4 depression (IFNL3 concentration 8.288 ± 1.696 pg/ml) than in those (N = 56) without complement C3 plus C4 depression (IFNL3 concentration 4.154 ± 0.4514 pg/ml). IFNL3 interferon-?3, SLEDAI Systemic Lupus Erythematosus Disease Activity Index
Supplier Page from CUSABIO Technology LLC for Human Interleukin 28B(IL-28B) ELISA Kit